In recent news, weight-loss medications have regained attention, particularly with Eli Lilly’s Mounjaro and Zepbound propelling the company to a historic trillion-dollar valuation. However, the advancements in GLP-1 agonist drugs, while promising for weight management, have brought to light several critical concerns. Research indicates that these medications may not only fall short in treating Alzheimer’s but also pose risks to pregnant women who discontinue usage, leading to potentially severe weight gain. Additionally, there’s growing apprehension among researchers regarding postpartum usage of these drugs for weight loss, highlighting the need for further investigation into their long-term effects and safety.
On a parallel front, the economic ramifications of artificial intelligence (AI) are under scrutiny as they reshape various markets. A special subscriber-only Roundtable, led by Mat Honan, will delve into these intricate dynamics, featuring insights from noted experts like David Rotman and Richard Waters. As AI technology continues its rapid evolution, understanding its broader implications is crucial. Recent discussions have shed light on the need for a balanced perspective regarding AI’s transformative potential—whether to embrace optimism or caution remains a nuanced debate. This ongoing dialogue aims to clarify the challenges and opportunities that AI presents to the economy at large.
Source: The Download: the mysteries surrounding weight-loss drugs, and the economic effects of AI via MIT Technology Review